MedPage Today (9/3, Monaco ) reports, “Two new studies published in JAMA Internal Medicine do not support a previously reported association between GLP-1 receptor agonists and a signal for suicidal ideation.” In one “analysis of nearly 300,000 new users of a GLP-1 agonist or SGLT2 inhibitor in Sweden and Denmark, primarily for diabetes, rates of suicide death over 2.5 years were not significantly different between groups, reaching 0.23 and 0.18 events per 1,000 person-years, respectively.” In the second study, researchers “pooled data from several of the STEP trials that supported semaglutide’s (Wegovy) weight-loss indication.” The “analysis showed that in STEP 1, 2, and 3, depression scores on the Patient Health Questionnaire-9 were lower at study end for patients on a 2.4-mg dose of semaglutide versus placebo recipients.”

Related Links:

— MedPage Today (requires login and subscription)

Psychiatric News (9/3) reports “cannabis use disorder and frequent cannabis use are linked to greater absenteeism at work, a study” found. Study “participants who used cannabis in the past month had a mean 1.47 days of missed work because of illness or injury, compared with 0.95 days for those who never used cannabis.” The findings were published in the American Journal of Preventive Medicine.

Related Links:

— “Cannabis Use Linked to Absenteeism at Work, Psychiatric News, September 3, 2024

The New York Times (9/1, Silver-Greenberg , Thomas) reported “Acadia Healthcare is one of America’s largest chains of psychiatric hospitals,” and “since the pandemic exacerbated a national mental health crisis, the company’s revenue has soared.” However, “a New York Times investigation found that some of that success was built on a disturbing practice: Acadia has lured patients into its facilities and held them against their will, even when detaining them was not medically necessary.” According to records, “in at least 12 of the 19 states where Acadia operates psychiatric hospitals, dozens of patients, employees and police officers have alerted the authorities that the company was detaining people in ways that violated the law.” In a number of “cases, judges have intervened to force Acadia to release patients.”

Related Links:

— “The New York Times (requires login and subscription)

Psychiatric News (8/30) reported, “A systematic analysis of brain imaging data from nearly 500 individuals suggests that a prevailing neurological hypothesis of autism spectrum disorder (ASD) – theorizing that people with ASD have poorer neural connections in certain brain regions relative to those without ASD – may not be accurate.” The researchers said, “It is important to note that we do not conclude that amygdala [connectivity] is generally typical in autism. Instead, we conclude that the evidence for atypical [connectivity] of the amygdala in autism is weak at best, and unreliable.” The findings were published in the American Journal of Psychiatry.

Related Links:

— “Study Uncovers No Strong Evidence That Autism Is Linked With Poor Amygdala Connectivity, Psychiatric News, August 30, 2024

Pharmacy Times (8/29, Halpern) reports, “Essential trials supporting the approvals of FDA breakthrough therapy-designated drugs often used surrogate markers as primary end points – even when not approved through the accelerated approval pathway – and often lacked post-marketing studies to confirm a drug’s clinical benefit, according to the results of a study.” These discoveries “could lead to uncertainties and confusion for both clinicians and patients surrounding the use of breakthrough therapy-designated drugs and suggest that the requiring of post-marketing studies – regardless of approval pathway – could heighten certainty that key stakeholders have in the expected clinical benefit.” The findings were published in JAMA Network Open.

Related Links:

— “Frequent Use of Surrogate Markers Could Create Uncertainty for Breakthrough-Designated Drugs,”Luke Halpern, Pharmacy Times , August 29, 2024